INTRODUCTION

The endothelium plays essential roles in modulating the tone of underlying vascular smooth muscle cells (VSMC) by synthesizing and releasing endothelium-derived relaxing factors (EDRFs), including vasodilator prostaglandins (e.g., prostacyclin), nitric oxide (NO) and endothelium-dependent hyperpolarization (EDH) factors. Thus, endothelial dysfunction is the hallmark of atherosclerotic cardiovascular diseases. Importantly, the contribution of EDRFs to endothelium-dependent vasodilatation varies in a distinct vessel size-dependent manner; NO mainly mediates vasodilatation of relatively large, conduit vessels (e.g., epicardial coronary arteries), while EDH factors in small resistance vessels (e.g., coronary microvessels). Endothelium-derived hydrogen peroxide ($H_2O_2$) is a physiological signalling molecule serving as one of the major EDH factors especially in microcirculations and has gained increasing attention in view of its emerging relevance for cardiovascular diseases. In the clinical settings, therapeutic approaches targeting NO (e.g., NO donors) or non-specific elimination of reactive oxygen species (e.g., antioxidant supplements) are disappointingly ineffective for the treatment of various cardiovascular diseases, in which endothelial dysfunction and coronary microvascular dysfunction are substantially involved. These lines of evidence indicate the potential importance of the physiological balance between NO and $H_2O_2$/EDH factor. Further characterization and better understanding of endothelium-dependent vasodilatations are important to develop novel therapeutic strategies in cardiovascular medicine. In this MiniReview, we will briefly summarize the current knowledge on the emerging regulatory roles of endothelium-dependent vasodilatations in the cardiovascular system, with a special reference to the two major EDRFs, NO and $H_2O_2$/EDH factor, in health and disease.

Keywords: endothelial function, endothelium, endothelium-dependent hyperpolarization, hydrogen peroxide, nitric oxide, nitric oxide synthase
arachidonic P450 epoxygenase pathway, electrical communication through gap junctions, K⁺ ions and as we demonstrated, endothelium-derived hydrogen peroxide (H₂O₂) (Figure 1). Although, by definition, the contribution of EDH factors is determined only after the blockade of both vaso-dilator prostaglandins and NO, EDH-mediated responses are the major mechanism of endothelium-dependent vasodilations in resistance arteries. The contribution of EDRFs to endothelium-dependent vasodilations markedly varies as a function of vessel size; endothelium-derived NO mainly mediates vasodilatation of relatively large, conduit vessels, while EDH-mediated responses are the predominant mechanisms of endothelium-dependent vasodilatation of resistance arteries. This vessel size-dependent contribution of NO and EDH factors is well preserved among species, from rodents to humans, to make a physiological balance between them.

Endothelial dysfunction is characterized by impaired production and/or action of EDRFs and serves as the hallmark and potential predictor for atherosclerotic cardiovascular diseases, as well as metabolic disorders. Various risk factors, such as smoking, diabetes mellitus, hypertension and hypercholesterolaemia, cause endothelial dysfunction, initiating the step towards atherosclerotic cardiovascular diseases. Endothelium-derived H₂O₂ is one of the major EDH factors in various vascular beds in animals and humans and has gained increasing attention in view of its emerging relevance for cardiovascular disease. In the clinical settings, it has been repeatedly reported that the effects of chronic nitrate therapy are neutral or even harmful in patients with cardiovascular diseases and that antioxidant treatments are disappointingly ineffective to prevent cardiovascular events. These lines of evidence suggest the importance of the physiological balance between NO and EDH factors in maintaining cardiovascular homeostasis and in curing diseases associated with endothelial dysfunction.

In this MiniReview, we will briefly summarize the current knowledge on the two endothelium-derived mediators, NO and EDH mediated by H₂O₂, with a special reference to their clinical implications and therapeutic approaches in cardiovascular diseases. An extensive review on the regulatory mechanisms of NO-mediated responses is available elsewhere.

ENDOTHELIAL MODULATION OF VASCULAR TONE: NO AND EDH

EDH factors cause hyperpolarization and subsequent relaxation of underlying VSMC with resultant vasodilatation of small resistance vessels and thus finely regulate blood pressure and tissue perfusion instantaneously in response to diverse physiological demands. As mentioned above, endothelium-derived NO and EDH factors share the roles in modulating vascular tone in a distinct vessel size-dependent fashion. Although prostaglandin E₂ and prostacyclin play important roles in the regulation of kidney functions,
such as glomerular filtration rate, renal blood flow and renal vascular tone, vasodilator prostaglandins in general play a small but constant role, independent of vessel size. NO predominantly regulates the tonus of relatively large conduit vessels (e.g., aorta and epicardial coronary arteries), while the importance of EDH factors increases as vessel size decreases (e.g., small mesenteric arteries and coronary microvessels). Thus, EDH-mediated vasodilatation is especially important in microcirculations, where blood pressure and tissue perfusion are critically determined. Moreover, such redundant mechanisms in endothelium-dependent vasodilations are advantageous for ensuring proper maintenance of vascular tone under pathological conditions, where one of EDRFs-mediated responses is compromised favouring a vasoconstrictor, prothrombotic and proinflammatory state. Indeed, in various pathological conditions with atherosclerotic risk factors, NO-mediated relaxations are easily impaired, while EDH-mediated responses are readily preserved or even enhanced to serve as a compensatory vasodilator system, although there are exceptions where after acute or chronic exposure to hyperglycaemia, these compensatory roles of EDH-mediated mechanisms are disrupted. Multiple mechanisms have been proposed for the enhanced EDH-mediated responses in small resistance vessels, including negative interactions between NO and several EDH factors, as discussed later. Although several EDH factors exist depending on the vascular bed, vessel size and species studied, endothelium-derived H2O2 at physiologically low concentrations is one of the major EDH factors in human and mouse small mesenteric arteries and human coronary arteries. Refer to an excellent textbook for more comprehensive information on other EDH factors. Next, we will focus on endothelium-derived H2O2 as an EDH factor in detail.

3 | ENDOTHELIUM-DERIVED H2O2 AS AN EDH FACTOR

3.1 | Identification of H2O2/EDH factor

H2O2 was acknowledged as a physiological signalling molecule serving especially in microcirculation for blood pressure, coronary microcirculation and metabolic functions. Reactive oxygen species (ROS) have been considered to be primarily harmful because of their highly damaging entity to cells and tissues and pathological implications in various cardiovascular diseases, including atherosclerosis, hypertension, heart failure, cardiomyopathy and coronary artery disease, where endothelial dysfunction is also substantially involved. However, as exemplified by endothelium-derived H2O2/EDH factor, a growing body of evidence has demonstrated that physiological levels of ROS can serve as crucial signalling molecules in health and disease. Following the original reports on the existence of EDH factors in 1988, four sets of early observations and notions led us to hypothesize that a putative EDH factor might be a non-NO vasodilator substance (likely ROS) derived from endothelial NO synthases (NOSs) system. Firstly, both NO-mediated and EDH-mediated responses are susceptible to vascular injuries caused by various atherosclerotic factors, and conversely, the treatment of those risk factors can restore both responses. Secondly, it was previously demonstrated that endothelium-derived free radicals exert vasoactive effects in endothelium-dependent vasodilatation and vasoconstriction in coronary arteries. Thirdly, both endothelial NOS (eNOS)-derived NO generation and EDH-mediated responses are dependent on calcium/calmodulin. Fourthly, a simple molecule (like NO) rather than complex substances may be favourable in modulating vascular tone instantaneously in response to physiological demands in the body. Thus, in 2000, we demonstrated for the first time that endothelium-derived H2O2 is an EDH factor in mouse mesenteric arteries; EDH-mediated hyperpolarizations and relaxations of underlying VSMC were inhibited by catalase, a specific H2O2 inhibitor, in small mesenteric arteries from wild-type mice and were significantly reduced in eNOS-knockout (KO) mice. This was also the case in other blood vessels, including human mesenteric and coronary arteries, porcine and canine coronary arteries and piglet pial arterioles. Several lines of evidence are available to support that H2O2 is a transferable factor derived from microvascular endothelium. For example, using a peroxide-sensitive fluorescence dye, we have previously demonstrated that an endothelium-dependent agonist acetylcholine induces endothelial production of H2O2, especially at the cell membrane, but not at the underlying vascular smooth muscle cell layer, in mouse small mesenteric arteries (approximately 200 μm in diameter) in the presence of a cyclooxygenase and a NO synthase inhibitors. Moreover, our electron spin resonance methods revealed that endothelial cells produce and release a significant amount of H2O2/EDH factor in porcine coronary microvessels. Furthermore, using a unique bioassay system, Liu et al. provided direct evidence that endothelium-derived H2O2 is a transferrable EDH factor mediating flow-mediated dilation in a paracrine manner in human coronary arterioles. Notably, the estimated concentrations of endothelium-derived H2O2/EDH factor were in micromolar order (<50 μmol/L), which are much lower concentrations than those observed in various pathological conditions. When applied exogenously in organ chamber experiments, approximately 10-100 μmol/L of H2O2 elicits vasodilatation of human coronary arterioles and mouse small mesenteric arteries, while higher concentrations of H2O2 rather induce vasoconstriction by releasing cyclooxygenase-derived thromboxane. It is important to note that only 10%-15% of H2O2 applied exogenously reaches the...
3.2 | Source of \( \text{H}_2\text{O}_2/\text{EDH factor} \)

Endothelium-derived \( \text{H}_2\text{O}_2 \) is mainly generated by the dismutation of superoxide anions derived from various sources in the endothelium, including NADPH oxidase, mitochondrial electron transport chain, xanthine oxidase, lipoygenase and NOSs (Figure 1). Cu,Zn-superoxide dismutase (SOD) plays a key role in the synthesis of \( \text{H}_2\text{O}_2/\text{EDH factor} \) in the endothelium. eNOS produces superoxide anions under physiological conditions when synthesizing NO from L-arginine and oxygen, while Cu,Zn-SOD dismutates those superoxide anions into \( \text{H}_2\text{O}_2 \). Moreover, Cu,Zn-SOD-KO mice show markedly impaired EDH-mediated hyperpolarizations and relaxations in mesenteric arteries and coronary circulation without VSMC dysfunction. Importantly, superoxide anions relevant to \( \text{H}_2\text{O}_2/\text{EDH factor} \) are not derived from pathologically uncoupled eNOS because \( \text{H}_2\text{O}_2 \)-mediated EDH-type responses are not cancelled by NOS inhibitors and up-regulation of eNOS cofactor tetrahydrobiopterin has no effects on the responses. It is widely accepted that NOS inhibitors (eg L-arginine analogues such as L-NNA and L-NAME) suppress superoxide generation from the oxygenase domain of eNOS or dysfunctional eNOS but not that from the reductase domain of eNOS, where superoxide generation is independent on the presence of Ca\(^{2+}/\text{CaM}\). In addition, Stuehr et al demonstrated that eNOS can generate superoxide anions from its reductase domain under physiological conditions, where superoxide anions are converted to \( \text{H}_2\text{O}_2 \) to cause EDH-mediated responses, and that NOS inhibitors (ie L-arginine analogues) only suppress superoxide generation from oxidase domain of eNOS. Previous studies by us and others have demonstrated that catalase significantly inhibits endothelium-dependent vasodilatation and hyperpolarization of small arteries in the absence of a NOS inhibitor. These lines of evidence support our notion that eNOS is the main source of \( \text{H}_2\text{O}_2 \) as an EDH factor under physiological conditions, although other sources of superoxide anions in \( \text{H}_2\text{O}_2 \)-mediated vasodilatation have been identified. For example, in human coronary arterioles, mitochondrial respiratory chain- and NADPH oxidase-derived \( \text{H}_2\text{O}_2 \) may be involved in flow-mediated dilatation and bradykinin-induced relaxation, respectively.

### 3.3 | Regulatory mechanisms of physiologically relevant \( \text{H}_2\text{O}_2 \)

Recent studies have provided potential regulatory mechanisms underlying the physiologically relevant \( \text{H}_2\text{O}_2 \) in the endothelium. It is important to note that local subcellular concentrations at microdomains rather than net cellular concentrations may be critical to determine whether the effects of ROS can be detrimental or beneficial for cellular signalling and that co-localization of the source and target of \( \text{H}_2\text{O}_2 \) may help avoid non-specific harmful oxidations. A good example of this concept is that only a minor increase in ROS caused by caveolar localization of NADPH oxidase-1 in hypertension is enough to interfere with NO-mediated signalling. In addition, specific cysteine residues, such as peroxiredoxins, can function as a redox-dependent molecular switch to regulate ROS-mediated signalling.

### 3.4 | Mode of action of \( \text{H}_2\text{O}_2/\text{EDH factor} \)

Oxidative modification of cyclic guanosine monophosphate (cGMP)-dependent protein kinase (PKG) is a central mechanism by which \( \text{H}_2\text{O}_2 \) induces hyperpolarization and relaxation of underlying VSMC, although other modes of action of \( \text{H}_2\text{O}_2/\text{EDH factor} \) have also been proposed. Briefly, \( \text{H}_2\text{O}_2 \) induces dimerization of 1α-isoforms of PKG (PKG1α) through an interprotein disulphide bond formation between them to enhance the kinase activity through phosphorylation. The activated PKG1α subsequently stimulates K\(^+\) channels with resultant hyperpolarization and vasodilatation in mouse mesenteric arteries and human coronary arteries. \( \text{H}_2\text{O}_2 \) also promotes the translocation of PKG1α from cytoplasm to membrane in human and porcine coronary arteries. Such reversible post-translational modification, like phosphorylation, is favourable for the fine control of vascular tone in response to demand fluctuation in vivo.

### 3.5 | Clinical significance of \( \text{H}_2\text{O}_2/\text{EDH factor} \)

The oxidant-mediated signalling by \( \text{H}_2\text{O}_2 \) is clinically important because it is associated with blood pressure control in vivo. Pharmacological inhibition of catalase, which decomposes \( \text{H}_2\text{O}_2 \) into oxygen and water, decreases arterial blood pressure associated with enhanced PKG1α dimerization in vivo. Moreover, the “redox-dead” knock-in mice of Cys42Ser PKG1α, whose mutant PKG1α is unable to be activated by \( \text{H}_2\text{O}_2 \)-induced dimerization because of the deletion in its redox-sensitive sulphur, exhibit markedly impaired EDH-mediated hyperpolarization and relaxation in resistance arteries ex vivo associated with systemic arterial hypertension in vivo. Furthermore, \( \text{H}_2\text{O}_2 \) has potent vasodilator properties in coronary resistance vessels and plays important roles in coronary autoregulation, cardioprotection against myocardial reperfusion injury and tachycardia-induced metabolic coronary vasodilatations in dogs in vivo. Given that coronary vascular resistance is
predominantly determined by the pre-arterioles and arterioles\(^{62}\) where the effect of EDH-mediated responses on vascular tone outweighs that of NO-mediated relaxations, it is important to maintain the vessel size-dependent contribution of NO and EDH factors for the treatment of coronary artery disease (CAD). Taken together, endothelium-derived \(\text{H}_2\text{O}_2\) functions as an important endogenous second messenger at its physiological low concentrations to elicit EDH-mediated vasodilatation and to maintain vascular homeostasis in the coronary circulation.\(^{2,10,39}\)

4 | MECHANISMS OF ENHANCED EDH IN MICROcirculation

4.1 | Diverse roles of endothelial NOSs system

The endothelium synthesizes and releases NO and \(\text{H}_2\text{O}_2/\text{EDH}\) factor to modulate vascular tone in a distinct vessel size-dependent manner through the diverse roles of endothelial NOSs system (Figure 2). In large conduit vessels, NOSs mainly serve as a NO-generating system to cause soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP)-mediated vasodilatation, whereas in small resistance vessels, they act as a superoxide-generating system to evoke \(\text{H}_2\text{O}_2/\text{EDH}\) factor-mediated responses.\(^{43}\) Superoxide anions derived from reductase domain of NOSs under physiological conditions are converted to \(\text{H}_2\text{O}_2\) to cause EDH-mediated responses.\(^{52}\) Among three NOS isoforms (neural NOS [nNOS, NOS1], inducible NOS [iNOS, NOS2] and eNOS, NOS3) expressed in cardiovascular system, eNOS is the dominant isoform in blood vessels\(^{63}\) and the most important isoform in generating \(\text{H}_2\text{O}_2/\text{EDH}\) factor in the endothelium.\(^{52}\) As mentioned above, genetic ablation of eNOS in mice results in impaired EDH-mediated vasodilatation associated with systemic hypertension.\(^{64}\) Using singly-eNOS-KO, doubly-n/eNOS-KO and triply-n/i/eNOS-KO mice, we have previously demonstrated that EDH-mediated relaxations are progressively reduced in accordance with the number of NOS genes ablated.\(^{43}\) As compared with wild-type mice, \(\text{H}_2\text{O}_2\)-mediated EDH-type relaxations of small mesenteric arteries are reduced approximately by half in singly-eNOS-KO mice, further diminished in doubly-n/eNOS-KO mice, and are finally absent in triply-n/i/eNOS-KO mice without underlying VSMC dysfunction.\(^{43}\) The remaining EDH-mediated relaxation of small mesenteric arteries in eNOS-KO mice is still sensitive to catalase.\(^{9}\) Collectively, these results indicate that three NOSs isoforms compensate each other to maintain \(\text{H}_2\text{O}_2\)-mediated EDH-type relaxations (Figure 2).

4.2 | Mechanisms for \(\text{H}_2\text{O}_2/\text{EDH}\) factor dominance in microcirculation

Accumulating evidence has provided mechanistic insights into vessel size-dependent contribution of NO and \(\text{H}_2\text{O}_2/\text{EDH}\) factor. Previous studies have shown that pre-treatment with NO donors attenuates EDH-mediated vasodilation in porcine coronary arteries in vitro\(^{65}\) and canine coronary microcirculation in vivo\(^{66}\) and that NO exerts a negative-feedback effect on endothelium-dependent vasodilatation through cGMP-mediated desensitization in canine coronary arteries ex vivo.\(^{67}\) Multiple mechanisms have been proposed for the negative interactions between NO and \(\text{H}_2\text{O}_2/\text{EDH}\) factor (Figure 3). Among them, cGMP-dependent activation of PKG desensitizes VSMC to \(\text{H}_2\text{O}_2\) by inhibiting \(\text{H}_2\text{O}_2\)-induced PKG1α dimerization, a central mechanism of \(\text{H}_2\text{O}_2/\text{EDH}\) factor-mediated vasodilatation, and in turn, pharmacological inhibition of sGC sensitizes conduit vessels, but not resistance vessels, to \(\text{H}_2\text{O}_2\)-induced vasodilatation in mice.\(^{68}\) In addition, mouse resistance vessels have less NO production and less antioxidant capacity, predisposing PKG1α to be more sensitive to \(\text{H}_2\text{O}_2\)-induced activation.\(^{68}\) Other key players for enhanced \(\text{H}_2\text{O}_2/\text{EDH}\) factor-mediated vasodilatation in resistance vessels include endothelial caveolin-1 (a negative regulator of eNOS)\(^{46,69}\) and α\(_1\)-subunit of endothelial AMP-activated protein kinase.\(^{46,70}\) In contrast, phosphorylation at Try657 of eNOS in response to \(\text{H}_2\text{O}_2\) leads to reduction in eNOS activity with resultant reduced NO production.\(^{71}\) Taken together, these mechanisms are in line with the widely accepted view that EDH-mediated responses function as a compensatory vasodilator system when NO-mediated relaxations are compromised. It is important to maintain the vessel size-dependent contribution of NO and EDH factors because excessive endothelial NO production by either caveolin-1 deficiency or eNOS overexpression disrupts the physiological balance between NO and EDH factors.
in endothelium-dependent vasodilatation, resulting in impaired cardiovascular homeostasis in mice in vivo.\textsuperscript{47,69}

5 | CLINICAL IMPLICATIONS

5.1 | Importance of endothelial function tests

Assessment of endothelial functions has been acknowledged as an excellent surrogate marker of cardiovascular events in many clinical settings, although it is challenging to accurately assess EDH-mediated responses especially in humans in vivo because the contribution of EDH factors could be determined only after the blockade of both vasodilator prostaglandins and NO. EDH-mediated vasodilation can be enhanced to compensate for impaired NO-mediated responses in the early stage of atherosclerotic conditions.\textsuperscript{10,23} However, after prolonged exposure to atherosclerotic risk factors, this compensatory role of EDH-mediated responses is eventually disrupted to cause metabolic disturbance.\textsuperscript{25} Endothelial dysfunction, as evaluated by impaired flow-mediated dilatation (FMD) of the brachial artery or digital reactive hyperaemia index (RHI) in peripheral arterial tonometry, is associated with future cardiovascular events in patients with coronary artery disease, and one standard deviation decrease in FMD or RHI is associated with doubling of cardiovascular event risk.\textsuperscript{72}

5.2 | Role of H$_2$O$_2$/EDH factor in the pathophysiology of coronary artery disease

Obviously, previous studies focused structural and functional abnormalities of “epicardial” coronary arteries in patients with CAD because they are easily visible on coronary angiography and amenable to procedural intervention (e.g., percutaneous coronary intervention). However, those of coronary microvasculature, referred to as coronary microvascular dysfunction (CMD), have gained increasing attention in view of their unexpectedly high prevalence in and significant prognostic impact in this population.\textsuperscript{73} The aetiologies of CMD still remain largely unknown and may be heterogeneous, for which several structural (e.g., vascular remodelling, vascular rarefaction and extramural compression) and functional abnormalities (e.g., endothelial dysfunction, VSMC dysfunction and microvascular spasm) have been proposed.\textsuperscript{62} Given that H$_2$O$_2$ has potent vasodilator properties in coronary resistance vessels where EDH-mediated responses become relatively dominant to NO-mediated relaxations, it is highly possible that impaired H$_2$O$_2$/EDH factor-mediated vasodilatation is involved in the pathogenesis of CMD. Indeed, in eNOS-KO mice, CMD mediated...
by H$_2$O$_2$/EDH factor is also present associated with cardiac diastolic dysfunction. Thus, for the treatment of CAD, it is essential to maintain the physiological balance between NO and H$_2$O$_2$/EDH factor, which notion is supported by the fact that significant negative interactions exist between NO and several EDH factors and that nitrates as NO donors are not beneficial for the treatment of CMD.

More recently, it has been highlighted that endothelium-dependent CMD is associated with low endothelial shear stress, larger plaque burden and vulnerable plaque characteristic beyond conventional coronary risk factors in angina patients with angiographically normal coronary artery or non-obstructive CAD. Altered oscillatory or low shear stress with disturbed flow on coronary artery wall is implicated in the local progression of atherosclerotic coronary plaque through endothelial and VSMC proliferation, inflammation, lipoprotein uptake and leucocyte adhesion.

5.3 Lessons from clinical trials targeting NO: too much of a good thing?

Although the role of CMD has been implicated in patients with obstructive CAD who underwent successful revascularization, the effects of isosorbide-5-mononitrate were unexpectedly neutral in patients with microvascular ischaemia despite successful percutaneous coronary intervention. Besides CAD, recent studies highlighted the high prevalence and pathophysiological relevance of CMD in patients with heart failure with preserved ejection fraction (HFpEF). Contrary to the premise that enhancing NO-mediated vasodilatation could exert beneficial effects on patients with HFpEF, the results of systemic and long-term administrations of inorganic nitrite in those patients were disappointing or even harmful in randomized, clinical trials. In a recent animal study, genetic ablation of endothelial arginase-1, an inhibitor of NO production, did not improve vasomotor function of resistance arteries in diabetic mice. Similarly, antioxidant therapies for patients with cardiovascular diseases had no benefits. These lines of evidence indicate that it is important to turn our attention to avoid excessive NO supplementation and to pay attention to the potential harm of non-specific elimination of ROS by antioxidants, although multiple mechanisms may be involved in the failure of antioxidant therapies, including inadequate dose, short treatment duration and pro-oxidant effects of antioxidants upon supplementation, and thus, so-called “antioxidant paradox” in clinical trials requires further investigations. An alternative explanation for such “paradox” of NO-targeted therapy may be nitrosative stress induced by an excessive amount of NO, again suggesting the importance of physiological balance between NO and EDH factors in endothelium-dependent vasodilatation. Standard medications used for the treatment of cardiovascular diseases in the current era share the pleiotropic effects on endothelial function by enhancing NO-mediated vasodilatation with modest antioxidant capacities, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and statins. Further research is warranted to address how to modulate CMD to improve clinical outcomes of patients with cardiovascular diseases.

6 CONCLUSIONS

This MiniReview highlighted the potential importance of the physiological balance between NO and H$_2$O$_2$/EDH factor in a distinct vessel size-dependent manner through the diverse functions of endothelial NOSs system in maintaining cardiovascular homeostasis. It remains an open question how to improve endothelial functions without affecting the delicate balance between NO and EDH factors. Further characterization and better understanding of endothelium-dependent vasodilatations are indispensable to this end, which helps us develop novel therapeutic strategies in cardiovascular medicine.

ACKNOWLEDGEMENTS

This work was supported in part by the Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan, and the Grants-in-Aid for Scientific Research from the Ministry of Health, Labour, and Welfare, Tokyo, Japan. The authors are deeply grateful to the late Professor Paul M. Vanhoutte for his lifelong support of our work.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES


71. Fleming I. Molecular mechanisms underlying the activation of eNOS. *Pflogers Arch*. 2010;459:793-806.


How to cite this article: Shimokawa H, Godo S. Nitric oxide and endothelium-dependent hyperpolarization mediated by hydrogen peroxide in health and disease. *Basic Clin Pharmacol Toxicol*. 2020;00:1–10. [https://doi.org/10.1111/bcpt.13377](https://doi.org/10.1111/bcpt.13377)